Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study.

Risk factors for unplanned discontinuation of scheduled treatment in elderly patients with castration-resistant prostate cancer: results of the IBuTu study. J Cancer Res Clin Oncol. 2018 Jan 04;: Authors: Honecker F, Wedding U, Kallischnigg G, Schroeder A, Klier J, Frangenheim T, Weißbach L Abstract PURPOSE: To gain knowledge about the factors associated with discontinuation of scheduled treatment in elderly men with castration-resistant prostate cancer (CRPC). METHODS: Patients ≥ 70 years with CRPC starting a new line of treatment were included in a prospective cohort study. A geriatric assessment (CGA) was performed at baseline, including comorbidity, mobility, functional/mental/nutritional status, as well as depression. Furthermore, pain intensity, quality of life, ECOG-performance status, and physicians' and patients' perception of health were documented. Reasons for and factors associated with discontinuation of scheduled treatment were analysed by univariate and multivariate analysis. RESULTS: After inclusion of 177 of 300 planned patients, the study was closed due to slow recruitment. 160 patients were eligible for final analysis. Median age was 77.5 years. 46% received chemotherapy, and 54% hormonal treatment. Discontinuation of scheduled treatment occurred in 91 patients (57.6%). The main reasons were progressive disease/death in 63%, adverse events/toxicity in 22%, and withdrawal of consent in 8%. In b...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research

Related Links:

In this study, the peel, pulp, and seeds of Vitis labrusca L. grapes were characterized by LC-DAD and ICP OES and changes in polyphenols, macro- and microelements were monitored using simulated human digestion. The pulp and seeds were characterized by flavanols, and the peels were high in phenolic acids. After the digestion, the highest bioaccessibility was found for quercetin (85%), while anthocyanins diglucosides were more bioaccessible in the gastric phase (153% and 113% for malvidin and cyanidin, respectively). The digestion of grape peels resulted in higher bioaccessibility of most minerals, suggesting the nutritional...
Source: Journal of Functional Foods - Category: Nutrition Source Type: research
Aeyung Kim, Jin Yeul Ma
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Gilead Sciences Inc. landed former Roche executive Daniel O'Day as its new CEO, and Genentech Inc.'s current CEO will take O'Day's role with Genentech's parent company in a game of musical chairs disclosed Sunday. The job shuffling has implications up and down the employment ranks of the Bay Area's two largest drug makers during critical times for both companies. Gilead (NASDAQ: GILD), based in Foster City, is set up for deeper moves into next-generation cancer drugs while South San Francisco's…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Two people developed cancer after organ donations from a woman who had the undetected disease.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news
This study explores the prevalence of clonal hematopoiesis related to radioactive iodine exposure and how it impacts overall survival in patients with thyroid cancer.Journal of Clinical Endocrinology &Metabolism
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Photo from ASCO Mediakit. © ASCO/Danny Morton 2017TheAnnual Meeting of the American Society of Clinical Oncology was last week. It ’s been my observation over the years that much of the best palliative-oncology and supportive-oncology research is presented at ASCO each year, before it’s actually published (if it ever gets published).  So I always dig through the palliative/EOL/supportive/psychooncology abstracts each year to see what's happening. Below is a gently annotated list of the abstracts that caught my eye the most, for your perusal and edification. Undoubtedly, these are my idiosyncratic...
Source: Pallimed: A Hospice and Palliative Medicine Blog - Category: Palliative Care Tags: ASCO cancer oncology pallonc research research issues rosielle WaPo Source Type: blogs
The past weekend we spent at Stanford Medicine X, listening to interesting and inspiring talks, and interacting with a diverse group of people and the ideas they brought with them. The event is designed to bring people from all aspects of medical car...
Source: Medgadget - Category: Medical Equipment Authors: Tags: Exclusive Oncology Psychiatry Source Type: blogs
This study builds on preliminary findings from the first phase of the INTERSTROKE study, which identified ten modifiable risk factors for stroke in 6,000 participants from 22 countries. The full-scale INTERSTROKE study included an additional 20,000 individuals from 32 countries in Europe, Asia, America, Africa and Australia, and sought to identify the main causes of stroke in diverse populations, young and old, men and women, and within subtypes of stroke. To estimate the proportion of strokes caused by specific risk factors, the investigators calculated the population attributable risk for each factor (PAR; an esti...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
By Stacy Simon The American Cancer Society and the American Society of Clinical Oncology have released a new Breast Cancer Survivorship Care Guideline to help breast cancer survivors and their primary care providers better manage their long-term care. The guideline was published December 7, 2015 in CA: A Cancer Journal for Clinicians, a journal of the American Cancer Society. It provides detailed recommendations for how and when to test for new or returning cancers, managing side effects, making healthy lifestyle changes, and coordinating care among primary care providers and specialists. The guideline is the third in a se...
Source: American Cancer Society :: News and Features - Category: Cancer & Oncology Tags: Breast Cancer Coping with Cancer Source Type: news
00:00 to 02.26—Dr. Bihari gives his background and credentials. Dr. Bihari: My medical training started at Harvard Medical School. I graduated in 1957. Then I trained in Internal Medicine at one of the Harvard teaching hospitals in Boston, Beth Israel, and then in Neurology at Massachusetts General in Boston. Then I went to the National Institutes of Health for two years doing brain physiology—brain research. I did another residency training in Psychiatry in New York, at Columbia Presbyterian Medical Center and then, over the following five or six years, I got very involved in working in Drug Addiction. By 197...
Source: HONEST MEDICINE: My Dream for the Future - Category: Consumer Health News Authors: Tags: Anecdotal Treatments HONEST MEDICINE Integrative Medicine Low Dose Naltrexone Obituaries Source Type: blogs
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Depression | Geriatrics | Hormones | Men | Nutrition | Pain | Prostate Cancer | Study | Toxicology